Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and alzheimer disease

Annals of Neurology

Volumn 76, Issue 6, 2014, Pages 813-825

  Agosta, Federica ^a   Libera, Dacia Dalla ^a   Spinelli, Edoardo Gioele ^a   Finardi, Annamaria ^a   Canu, Elisa ^a   Bergami, Alessra ^a   Chiavetto, Luisella Bocchio ^b   Baronio, Manuela ^c   Comi, Giancarlo ^a,d   Martino, Gianvito ^a   Matteoli, Michela ^e,f   Magnani, Giuseppe ^a   Verderio, Claudia ^e,f   Furlan, Roberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c Poliambulanza Foundation Hospital   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e CNR   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; MYELIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CLINICAL EVALUATION; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE VESICLE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; MYELIN DEFICIENCY; MYELOID MICROVESICLE; NERVE CELL DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; WHITE MATTER LESION; BONE MARROW CELL; CELL COUNT; METABOLISM; MIDDLE AGED; MYELIN SHEATH; NERVE CELL; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CELL COUNT; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MYELIN SHEATH; MYELOID CELLS; NEURONS;

EID: 84913583564     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24235     Document Type: Article

References (67)

1. Miller AE, Neighbour PA, Katzman R, et al. Immunological studies in senile dementia of the Alzheimer type: evidence for enhanced suppressor cell activity. Ann Neurol 1981;10:506-510.
2. Tollefson GD, Godes M, Warren JB, et al. Lymphopenia in primary degenerative dementia. J Psychiatr Res 1989;23:191-199.
3. Fernandez PL, Britton GB, Rao KS. Potential immunotargets for Alzheimer's disease treatment strategies. J Alzheimers Dis 2013; 33:297-312.
4. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol 2010;119:89-105.
5. Joshi P, Turola E, Ruiz A, et al. Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles. Cell Death Differ 2013;21:582-593.
6. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996;55:1083-1088.
7. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008;32:412-419.
8. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009;72:56-62.
9. Serrano-Pozo A, Mielke ML, Gomez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol 2011;179:1373-1384.
10. Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 2014;88:495-498.
11. Naert G, Rivest S. A deficiency in CCR21 monocytes: the hidden side of Alzheimer's disease. J Mol Cell Biol 2013;5:284-293.
12. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009;19:43-51.
13. Bianco F, Perrotta C, Novellino L, et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. EMBO J 2009;28:1043-1054.
14. Bianco F, Pravettoni E, Colombo A, et al. Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 2005;174:7268-7277.
15. Verderio C, Muzio L, Turola E, et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol 2012;72:610-624.
16. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-fac-tor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106:1604-1611.
17. Gonnord P, Delarasse C, Auger R, et al. Palmitoylation of the P2X7 receptor, an ATP-gated channel, controls its expression and association with lipid rafts. FASEB J 2009;23:795-805.
18. Antonucci F, Turola E, Riganti L, et al. Microvesicles released from microglia stimulate synaptic activity via enhanced sphingolipid metabolism. EMBO J 2012;31:1231-1240.
19. Garzetti L, Menon R, Finardi A, et al. Activated macrophages release microvesicles containing polarized M1 or M2 mRNAs. J Leukoc Biol (in press).
20. Colombo E, Borgiani B, Verderio C, Furlan R. Microvesicles: novel biomarkers for neurological disorders. Front Physiol 2012;3:63.
21. Agosta F, Pievani M, Sala S, et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 2011;258:853-863.
22. Pievani M, Agosta F, Pagani E, et al. Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp 2010;31:1862-1875.
23. Rowley J, Fonov V, Wu O, et al. White matter abnormalities and structural hippocampal disconnections in amnestic mild cognitive impairment and Alzheimer's disease. PLoS One 2013; 8:e74776.
24. Zhuang L, Sachdev PS, Trollor JN, et al. Microstructural white matter changes in cognitively normal individuals at risk of amnestic MCI. Neurology 2012;79:748-754.
25. Krstic D, Knuesel I. Deciphering the mechanism underlying lateonset Alzheimer disease. Nat Rev Neurol 2013;9:25-34.
26. Filippi M, Canu E, Agosta F. The role of amyloid-beta, tau, and apolipoprotein E epsilon4 in Alzheimer disease: how is the team playing? AJNR Am J Neuroradiol 2013;34:511-512.
27. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
28. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.
29. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
30. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
31. Mauri M, Carlesimo GA, Graceffa AMS, et al. Standardizzazione di due nuovi test di memoria: apprendimento di liste di parole correlate e non correlate semanticamente. Arch Psicol Neurol Psichiatr 1997;58:621-645.
32. Orsini A, Grossi D, Capitani E, et al. Verbal and spatial immediate memory span: normative data from 1355 adults and 1112 children. Ital J Neurol Sci 1987;8:539-548.
33. Caffarra P, Vezzadini G, Dieci F, et al. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002;22:443-447.
34. Basso A, Capitani E, Laiacona M. Raven's coloured progressive matrices: normative values on 305 adult normal controls. Funct Neurol 1987;2:189-194.
35. Spinnler H, Tognoni G. Standardizzazione e taratura Italiana di test neuropsicologici. Ital J Neurol Sci 1987;6:1-120.
36. Novelli G, Papagno C, Capitani E, et al. Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali. Arch Psicol Neurol Psichiatr 1986;47:477-506.
37. De Renzi E, Vignolo LA. The token test: a sensitive test to detect receptive disturbances in aphasics. Brain 1962;85:665-678.
38. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95-113.
39. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
40. Canu E, Agosta F, Spinelli EG, et al. White matter microstructural damage in Alzheimer's disease at different ages of onset. Neurobiol Aging 2013;34:2331-2340.
41. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1-25.
42. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44: 83-98.
43. Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358:201-205.
44. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
45. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
46. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-223.
47. Naert G, Rivest S. Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med 2012;18:297-313.
48. Jaturapatporn D, Isaac MG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012;2:CD006378.
49. Bhaskar K, Konerth M, Kokiko-Cochran ON, et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010;68:19-31.
50. Saman S, Kim W, Raya M, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 2011; 287:3842-3849.
51. Cagnin A, Kassiou M, Meikle SR, Banati RB. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand Suppl 2006;185:107-114.
52. Carter SF, Scholl M, Almkvist O, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 2012;53:37-46.
53. Pierpaoli C, Barnett A, Pajevic S, et al. Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage 2001;13:1174-1185.
54. Wheeler-Kingshott CA, Cercignani M. About "axial" and "radial" diffusivities. Magn Reson Med 2009;61:1255-1260.
55. Carmeli C, Donati A, Antille V, et al. Demyelination in mild cognitive impairment suggests progression path to Alzheimer's disease. PLoS One 2013;8:e72759.
56. Wang DS, Bennett DA, Mufson EJ, et al. Contribution of changes in ubiquitin and myelin basic protein to age-related cognitive decline. Neurosci Res 2004;48:93-100.
57. Horiuchi M, Maezawa I, Itoh A, et al. Amyloid beta1-42 oligomer inhibits myelin sheet formation in vitro. Neurobiol Aging 2012;33: 499-509.
58. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005;8:1051-1058.
59. Kolodziejczyk K, Hamilton NB, Wade A, et al. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 2009;132:1496-1508.
60. Khorooshi R, Owens T. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol 2010;185:1258-1264.
61. Piehl F, Lundberg C, Khademi M, et al. Non-MHC gene regulation of nerve root injury induced spinal cord inflammation and neuron death. J Neuroimmunol 1999;101:87-97.
62. Ahmed Z, Cooper J, Murray TK, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol 2014;127:667-683.
63. Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging 2012;33:828.e19-828.e30.
64. Reid AT, Evans AC. Structural networks in Alzheimer's disease. Eur Neuropsychopharmacol 2013;23:63-77.
65. Olson L, Humpel C. Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment. Exp Gerontol 2010;45:41-46.
66. Teipel SJ, Grothe M, Lista S, et al. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am 2013;97:399-424.
67. Blennow K, Zetterberg H. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am 2013;97:369-376.